A lot of health-care industry planning for the future has happened in the ten years since the UK Office for Life Sciences (OLS) was set up as a bridge between the health and business ministries’ areas of responsibility around innovation, clinical research and market access. The OLS was founded to create a virtuous circle, bringing together health and wealth, and including job creation and the development of health technology for patients in the UK, enabling them to swiftly return to being contributors to the economy. (Also see "UK medtech needs to seize moment and make most of OLS" - Medtech Insight, 22 July, 2009.)
UK Plugs Into ‘Golden Period’ For Medtech Innovation
The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.
More from United Kingdom
More from Europe
• By
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.
• By
A seemingly humorous social media post on April Fool’s Day struck a nerve with regulatory experts, reflecting real concerns about recent actions by the US Food and Drug Administration.
• By
Cybersecurity, sustainability and regulatory intelligence all need factoring into risk management today as AI and data availability change the goalposts. Eight experts tell Medtech Insight how compliance efforts must adapt.